STAT+: Sanofi, Regeneron expand partnership after Dupixent success

Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories

Why it mattersFederal officials and health care executives rubbed elbows at the ritzy MAHA Summit, causing some supporters to question what MAHA has become.

Why it mattersSome lawmakers are urging the Trump administration to rethink a pending rule that may prevent Americans from obtaining medicines from licensed international pharmacies.